New
HealthMore in Health→
Five-Year Survival Data Reinforce Neoadjuvant Immunotherapy in Melanoma
Key Takeaways
- The International Neoadjuvant Melanoma Consortium published an updated pooled analysis in Nature Medicine on 1 October 2026.
- The analysis covers three-year and five-year survival plus other outcome data for 1,038 melanoma patients treated with neoadjuvant therapy.
- Neoadjuvant immune checkpoint inhibitors are already standard of care for resectable stage IIIB–D melanoma.
- Authors state that knowledge gaps remain regarding optimal treatment type and long-term survival determinants.
DE
DT Editorial Team··via nature.com